文献速递骨质疏松与钙磷/甲状旁腺

甲状旁腺功能减退症:维生素D2治疗相比骨化三醇的低钙血症更轻

Hypoparathyroidism: Less Severe Hypocalcemia With Treatment With Vitamin D2 Compared With Calcitriol.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

回顾性研究比较甲状旁腺功能减退症患者长期使用维生素D2(16例)或骨化三醇(14例)的肾功能、高钙血症和低钙血症。维生素D2组因低钙血症住院或急诊就诊为0例,骨化三醇组为14例中4例(P=0.03)。两组在高钙血症住院或急诊、血肌酐、血钙或肾结石方面无差异。

要点

  • 维生素D2组因低钙血症住院或急诊就诊0例,骨化三醇组14例中4例(P=0.03)。
  • 两组在高钙血症住院或急诊、血肌酐、血钙或肾结石方面无差异。
  • 作者认为甲状旁腺功能减退症患者应考虑使用维生素D2治疗,尤其反复发生低钙血症者。

核心结论

  • 长期使用维生素D2治疗的甲状旁腺功能减退症患者相比骨化三醇治疗者低钙血症相关疾病负担更少,且肾功能或高钙血症相关疾病负担无差异。
  • 作者认为甲状旁腺功能减退症患者应考虑使用维生素D2治疗,尤其反复发生低钙血症者。

研究设计与样本

  • 回顾性研究,纳入马里兰大学医院收治的甲状旁腺功能减退症患者,通过账单记录搜索识别、病历审查确认诊断,共30例,其中16例长期使用维生素D2、14例使用骨化三醇,数据从病历中提取。

主要发现

  • 维生素D2组与骨化三醇组年龄分别为58.9 ± 16.7岁与50.9 ± 22.6岁(P = 0.28),性别和治疗时长分别为17.8 ± 14.2年与8.5 ± 4.4年(P = 0.076)。
  • 因低钙血症住院或急诊就诊:维生素D2组0例,骨化三醇组14例中4例(P = 0.03),其中骨化三醇组3例有多次急诊就诊。
  • 两组在高钙血症住院或急诊就诊、血肌酐、血钙或肾结石方面无差异。

临床怎么用

  • 作者认为甲状旁腺功能减退症患者应考虑使用维生素D2治疗,尤其反复发生低钙血症者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Options for chronic treatment of hypoparathyroidism include calcitriol, recombinant human parathyroid hormone, and high-dose vitamin D (D2). D2 is used in a minority of patients because of fear of prolonged hypercalcemia and renal toxicity. There is a paucity of recent data about D2 use in hypoparathyroidism. OBJECTIVE: Compare renal function, hypercalcemia, and hypocalcemia in patients with hypoparathyroidism treated chronically with either D2 (D2 group) or calcitriol. DESIGN, SETTING, AND PATIENTS: A retrospective study of patients with hypoparathyroidism treated at the University of Maryland Hospital. Participants were identified by a billing record search with diagnosis confirmed by chart review. Thirty patients were identified; 16 were treated chronically with D2, 14 with calcitriol. Data were extracted from medical records. MAIN OUTCOME MEASURES: Serum creatinine and calcium, hospitalizations, and emergency department (ED) visits for hypercalcemia and hypocalcemia. RESULTS: D2 and calcitriol groups were similar in age (58.9 ± 16.7 vs 50.9 ± 22.6 years, P = 0.28), sex, and treatment duration (17.8 ± 14.2 vs 8.5 ± 4.4 years, P = 0.076). Hospitalization or ED visits for hypocalcemia occurred in none of the D2 group vs four of 14 in the calcitriol group (P = 0.03); three in the calcitriol group had multiple ED visits. There were no differences between D2 and calcitriol groups in hospitalizations or ED visits for hypercalcemia, serum creatinine or calcium, or kidney stones. CONCLUSION: We found less morbidity from hypocalcemia in hypoparathyroid patients treated chronically with D2 compared with calcitriol and found no difference in renal function or morbidity from hypercalcemia. Treatment with D2 should be considered in patients with hypoparathyroidism, particularly in those who experience recurrent hypocalcemia.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Streeten EA, Mohtasebi Y, Konig M, et al. Hypoparathyroidism: Less Severe Hypocalcemia With Treatment With Vitamin D2 Compared With Calcitriol. J Clin Endocrinol Metab. 2017. PMID: 28324108. doi:10.1210/jc.2016-3712

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。